<DOC>
	<DOCNO>NCT00025350</DOCNO>
	<brief_summary>RATIONALE : Biological therapy gefitinib may interfere growth tumor cell slow growth recurrent metastatic colorectal cancer . PURPOSE : Randomized phase II trial compare effectiveness two different dos gefitinib treat patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 4-month progression-free survival rate patient recurrent metastatic colorectal adenocarcinoma treat gefitinib . - Determine objective tumor response rate , progression , overall survival patient treated drug . - Determine toxicity drug patient . OUTLINE : This randomize , double-blind study . Patients stratify accord ECOG performance status ( 0-1 v 2 ) , baseline serum CEA ( less 5 mg/L v least 5 mg/L ) , number metastatic site ( 1 vs 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral gefitinib daily ( twice daily day 1 course 1 ) . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive high dose oral gefitinib arm I . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven adenocarcinoma colon rectum Measurable disease Evidence new progressive metastatic disease within 6 month last treatment Must receive prior systemic treatment fluorouracil ( and/or analog , without leucovorin calcium levamisole ) irinotecan adjuvant metastatic setting Metastatic tumor site accessible biopsy No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 5 time ULN tumor involvement liver ) Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active uncontrolled infection Other prior malignancy allow provided prior therapy discontinue evidence disease No uncontrolled illness psychiatric illness/social situation would preclude study Must able take retain oral medication PRIOR CONCURRENT THERAPY : Biologic therapy : No prior signal transduction inhibitor ( e.g. , vascular endothelial growth factor , vascular endothelial growth factor receptor , epidermal growth factor receptortargeted agent ) colorectal cancer Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover No prior cytotoxic chemotherapy ( e.g. , oxaliplatin ) colorectal cancer Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : No prior systemic therapy colorectal cancer No prior investigational approve agent colorectal cancer No concurrent investigational agent No concurrent antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>